SURGICAL BLEEDING AND THE USE OF HAEMOSTATS
Intra-operative bleeding can extend overall operative and anaesthetic time, potentially increasing both the risks of patient morbidity and mortality, and total healthcare costs. Haemostats are used to treat persistent bleeding from tissue beds or small blood vessels that cannot be treated effectively with conventional methods, while haemostatic sealants provide bleeding control and help to seal wounds. While standard haemostats (such as gelatin sponges) cost around €5-15 per dose, fibrin sealants in patch or liquid form can cost over €200 per dose. In addition to their high price, currently marketed products suffer from other problems which limit their widespread adoption. For example, some market leading products are unable to control stronger bleeds, while others contain blood-derived thrombin and fibrinogen.